IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4092-4103

  Sung, Wen Wei ^a   Wang, Yao Chen ^a,b   Lin, Po Lin ^a   Cheng, Ya Wen ^d   Chen, Chih Yi ^a   Wu, Tzu Chin ^b   Lee, Huei ^a,c,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Institute of Medicine China Medical University Hospital ^*  (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GENOMIC DNA; INTERLEUKIN 10; MESSENGER RNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN CIP2A; PROTEIN E6; UNCLASSIFIED DRUG; WORTMANNIN; AUTOANTIGEN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; IL10 PROTEIN, HUMAN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; REPRESSOR PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR REGRESSION; WART VIRUS; ADENOCARCINOMA; ANIMAL; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; METABOLISM; PATHOLOGY; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; ANIMALS; AUTOANTIGENS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-10; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; ONCOGENE PROTEINS, VIRAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881256573     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3439     Document Type: Article

References (45)

1. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
2. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020-8.
3. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006;12:1301-9.
4. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
5. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005;50:291-7.
6. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, et al. Prognostic factors in resected stage I non-small cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004;22:4575-83.
7. Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, et al. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2003;9: 1785-91.
8. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, et al. Serum interleukin-10 levels as a prognostic factor in advanced nonsmall cell lung cancer patients. Chest 2000;117:365-73.
9. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61: 2799-803.
10. Cheng YW,WuMF, Wang J, Yeh KT, Goan YG, Chiou HL, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007;67:10686-93.
11. Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-Alpha in cervical squamous intraepithelial lesions. Hum Pathol 2004;35: 1376-84.
12. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005;58:1096-100.
13. Sharma A, Rajappa M, Saxena A, Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007;17:879-85.
14. Fernandes AP, Goncalves MA, Duarte G, Cunha FQ, Simoes RT, Donadi EA. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels. Virology 2005;334:294-8.
15. zur Hausen H. Papillomaviruses causing cancer: evasion from hostcell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
16. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
17. El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol 2001;195: 179-85.
18. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H. Reduced p21 (WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-Associated lung cancer. Clin Cancer Res 2011;17:1895-905.
19. Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 2011;17:5991-9.
20. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130: 51-62.
21. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Presence and potent immunosuppressive role of interleukin-10 in malignant pleural effusion due to lung cancer. Cancer Lett 1999; 136:27-32.
22. Hatanaka H, Abe Y, Naruke M, Tokunaga T, Oshika Y, Kawakami T, et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res 2001;7:1287-92.
23. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78: 1043-51.
24. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994;145:18-25.
25. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995;55:3847-53.
26. Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, et al. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 2004;64:1843-52.
27. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006;66:1491-9.
28. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, et al. Increased IL-10 mRNA expression in tumor-Associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 2011;30:62.
29. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 2007;30:627-32.
30. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83.
31. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012;72:420-9.
32. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996;2:1969-79.
33. Zeng L, O'Connor C, Zhang J, Kaplan AM, Cohen DA. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 2010;49:294-302.
34. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 2000;11:815-9.
35. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-81.
36. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008;226:205-18.
37. Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, et al. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/ phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res 2010;16:5200-10.
38. Xu P, Xu XL, Huang Q, Zhang ZH, Zhang YB. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol 2012;29:1643-7.
39. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS ONE 2011;6:e20159.
40. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011;18:857-65.
41. Chen KF, LiuCY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010;29:6257-66.
42. Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 2012;48: 585-93.
43. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012;14:R68.
44. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, Chen KF. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett 2012;317:9-15.
45. Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, Hou DR, et al. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther 2011;10: 892-901.